ZS Pharma, Inc. Net Income
ZS Pharma, Inc. reported Net Income of -$35.35 million for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-09.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2015-11-09
- ZS Pharma, Inc. net income (loss) attributable to parent for the quarter ending 2015-09-30 was -$35.35M.
- ZS Pharma, Inc. net income (loss) attributable to parent for the quarter ending 2015-06-30 was -$32.60M.
- ZS Pharma, Inc. net income (loss) attributable to parent for the quarter ending 2015-03-31 was -$21.95M.
- ZS Pharma, Inc. net income (loss) attributable to parent for the quarter ending 2014-12-31 was -$20.32M.
- ZS Pharma, Inc. net income (loss) attributable to parent for fiscal 2014 was -$64.35M.
- ZS Pharma, Inc. net income (loss) attributable to parent for fiscal 2013 was -$34.29M.
- ZS Pharma, Inc. net income (loss) attributable to parent for fiscal 2012 was -$10.46M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2015-09-30 | -$35.35M 10-Q · filed 2015-11-09 | -$67.95M derived: sum of 2 quarters · filed 2015-11-09 | -$89.90M 10-Q · filed 2015-11-09 | -$110.21M derived: sum of 4 quarters · filed 2015-11-09 |
| 2015-06-30 | -$32.60M 10-Q · filed 2015-08-06 | -$54.55M 10-Q · filed 2015-08-06 | -$74.86M derived: sum of 3 quarters · filed 2015-08-06 | -$91.73M derived: sum of 4 quarters · filed 2015-11-09 |
| 2015-03-31 | -$21.95M 10-Q · filed 2015-05-11 | -$42.26M derived: sum of 2 quarters · filed 2015-05-11 | -$59.12M derived: sum of 3 quarters · filed 2015-11-09 | -$75.55M derived: sum of 4 quarters · filed 2015-11-09 |
| 2014-12-31 | -$20.32M 10-K · filed 2015-03-13 | -$37.18M derived: sum of 2 quarters · filed 2015-11-09 | -$53.61M derived: sum of 3 quarters · filed 2015-11-09 | -$64.35M 10-K · filed 2015-03-13 |
| 2014-09-30 | -$16.86M 10-Q · filed 2015-11-09 | -$33.29M derived: sum of 2 quarters · filed 2015-11-09 | -$44.04M 10-Q · filed 2015-11-09 | -$55.88M derived: sum of 4 quarters · filed 2015-11-09 |
| 2014-06-30 | -$16.43M 10-Q · filed 2015-08-06 | -$27.18M 10-Q · filed 2015-08-06 | -$39.01M derived: sum of 3 quarters · filed 2015-08-06 | -$48.58M derived: sum of 4 quarters · filed 2015-08-06 |
| 2014-03-31 | -$10.75M 10-Q · filed 2015-05-11 | -$22.59M derived: sum of 2 quarters · filed 2015-05-11 | -$32.15M derived: sum of 3 quarters · filed 2015-05-11 | -$39.64M derived: sum of 4 quarters · filed 2015-05-11 |
| 2013-12-31 | -$11.84M 10-K · filed 2015-03-13 | -$21.40M derived: sum of 2 quarters · filed 2015-03-13 | -$28.89M derived: sum of 3 quarters · filed 2015-03-13 | -$34.29M 10-K · filed 2015-03-13 |
| 2013-09-30 | -$9.56M 10-K · filed 2015-03-13 | -$17.05M derived: sum of 2 quarters · filed 2015-03-13 | -$22.45M 10-Q · filed 2014-11-10 | |
| 2013-06-30 | -$7.49M 10-K · filed 2015-03-13 | -$12.88M 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | -$5.40M 10-K · filed 2015-03-13 | |||
| 2012-12-31 | -$10.46M 10-K · filed 2015-03-13 |